Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q3 FY25 results · Oct–Dec 2024
Ajanta Pharma reported revenue from operations of ₹1,146.13 crore (up 3.7% from Q3 FY24) and net profit of ₹232.88 crore (up 10.9% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,146.13 | 1,105.15 | +3.7% | 1,186.64 | −3.4% |
| Other income | 30.44 | 13.59 | +124.0% | 19.48 | +56.3% |
| Total income | 1,176.57 | 1,118.74 | +5.2% | 1,206.12 | −2.5% |
| Profit before tax | 307.39 | 290.91 | +5.7% | 290.24 | +5.9% |
| Net profit for the period | 232.88 | 210.03 | +10.9% | 216.48 | +7.6% |
| EPS, basic (₹) | 18.60 | 16.68 | +11.5% | 17.27 | +7.7% |
| Net margin (%) | 20.3 | 19.0 | 18.2 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,101.92 | 1,085.29 | +1.5% | 1,128.91 | −2.4% |
| Other income | 33.23 | 13.73 | +142.0% | 40.34 | −17.6% |
| Total income | 1,135.15 | 1,099.02 | +3.3% | 1,169.25 | −2.9% |
| Profit before tax | 332.15 | 305.14 | +8.9% | 309.20 | +7.4% |
| Net profit for the period | 252.45 | 220.15 | +14.7% | 234.98 | +7.4% |
| EPS, basic (₹) | 20.16 | 17.48 | +15.3% | 18.75 | +7.5% |
| Net margin (%) | 22.9 | 20.3 | 20.8 |
Consolidated
- Filed with BSE
- 30 Jan 2025, 17:24 IST
- Board meeting
- 30 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jan 2025, 17:24 IST
- Board meeting
- 30 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE